Overview

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Phase:

Phase 2

Details

Lead Sponsor:

Muhammad Furqan

Collaborator:

AstraZeneca

Treatments:

Carboplatin
Durvalumab
Etoposide